phase. Results: The mean incidence of IME was 0.15 IME per treatment, and there was no statistical difference between oHDF and HD. A higher haematocrit (oHDF 31.5% vs. HD 30.5%, p ! 0.01) at a lower erythropoietin dose (oHDF 4,913 vs. HD 5,492 IU/week, p = 0.02) was found during oHDF, when the sequence of HD and oHDF had not been taken into account. For the study groups, the results were less distinct: in group A, a higher haematocrit (HD 30.4% vs. oHDF 32.0%, p ! 0.01) at a comparable erythropoietin dose (HD 5,421 vs. oHDF 5,187 IU/week, ns) was observed during oHDF, whereas in group B an identical haematocrit (oHDF 30.8% vs. HD 30.7%, ns) was achieved at a reduced erythropoietin dose (oHDF 4,622 vs. HD 5,568 IU/week, p ! 0.01). During oHDF, lower levels of free and protein-bound pentosidine and of serum phosphate were found. Conclusion: In contrast to other studies, no benefi t regarding cardiovascular stability for oHDF was found, but oHDF could well offer a potential benefi t regarding anaemia correction, infl ammation, oxidative stress, lipid profi les, and calcium-phosphate product.
Introduction
In chronic kidney disease patients, haemodialysis (HD) does not provide suffi cient clearance for the removal of middle and high molecular uraemic toxins such as ␤ 2 -microglobulin; the diffusive transport becomes ineffective with increasing molecular weight of the solute. In comparison to standard HD, the combination of diffusion and convection by on-line haemodiafi ltration (oHDF) is characterised by high elimination rates for the middle molecular weight solutes [1, 2] . This is suggested to be associated with the observed clinical benefi t of oHDF [3] [4] [5] [6] [7] . Moreover, a better intradialytic cardiovascular stability was reported [8] , but never in a controlled randomised trial. This was therefore the primary objective of this investigation.
Anaemia in HD patients is a complex syndrome, and many other factors besides relative or absolute erythropoietin defi ciency may contribute to its pathogenesis. Microbiological and pyrogenic contamination of dialysate also plays a role in aggravating infl ammation and thereby anaemia [9] . With double stage fi ltration, oHDF provides microbiologically safe substitution fl uid by effi cient retention of microorganisms, endotoxins and other cytokine-inducing substances compared to conventional HD carried out without ultrapure dialysate [10, 11] . Whereas in one study an increase of the haemoglobin levels was observed after the switch from HD (with cuprophane dialysers) to oHDF (with polysulfone and polyamide dialysers) [7] , other studies could not confi rm the positive impact of oHDF on anaemia [6, 12] . These results are confl icting, but the possibility that oHDF may achieve a better control in anaemia is intriguing. Therefore, the effect of oHDF on anaemia was investigated as a major secondary objective in a cross-over study with identical membranes, taking into consideration further factors potentially affecting erythropoiesis.
In HD with low-fl ux membranes the diffusive transport is nearly identical to the total transport, whereas in HD with high-fl ux membranes additionally convective transport takes place due to internal fi ltration over the membrane [13] . In oHDF, the convective transport is increased with the infusion rate of the on-line prepared substitution fl uid [14] . Therefore, a study on the infl uence of convection during dialysis should include the comparison between HD with a low-fl ux membrane (representing predominantly diffusive solute transport) and oHDF with a high-fl ux membrane and a high substitution rate (representing a highly convective solute transport additionally to the diffusive solute transport). For this comparison the membrane material should be identical to eliminate interfering effects. Compared to HD, the dialysis dose of oHDF is usually higher due to its additional convective clearance. Thus, the benefi t of oHDF compared to HD reported in most of the studies might at least partly be a consequence of the higher dialysis dose of oHDF. To minimise such a bias, the aim was to keep treatment dose suffi ciently high in both treatment modes (eKt/V 6 1.2) and as close as possible to each other.
Subjects and Methods

Study Design and Patients
The study was designed as an open, randomised, prospective multi-centre trial with cross-over design. Seven dialysis units in Hungary participated in the study. Local legal and administrative regulations were followed, and approval of the respective Ethics Committees was obtained.
All adult patients with chronic kidney failure in the participating centres were asked to participate if no exclusion criteria (pregnancy, lactation, infectious diseases, simultaneous participation in another clinical trial) applied and they had been on HD treatment for at least 3 months. All patients gave their written informed consent. After a pre-phase of 3 months with low-fl ux HD using cuprophane membranes, all patients were randomised to group A or B. Randomisation was centrally performed by an independent institute. A random code was used, with a separate list for each study centre. Patients who dropped out of the study were not replaced.
Patients in group A started with HD using low-fl ux polysulfone membranes, patients in group B started with oHDF using high-fl ux polysulfone membranes. After 24 weeks, both groups switched over to the other treatment mode for further 24 weeks. Following the study protocol, the same minimum dialysis dose (eKt/V 6 1.2) was required in each study phase; necessary adaptations, e.g. changing blood fl ow and/or size of the dialyser, were made during the fi rst 3 weeks of each study phase, if patients were repeatedly below 1.2, they had to be withdrawn from the study.
Study Treatment
HD and oHDF were performed with 4008 HD machines from Fresenius Medical Care. In the pre-phase, low-fl ux cuprophane membranes (Focus 120 R, National Medical Care) were used, in the HD phase low-fl ux polysulfone dialysers (HPS series, Fresenius Medical Care), and in the oHDF phase high-fl ux polysulfone dialysers (Fresenius Medical Care). Dialysate fi lters (Diasafe ® , Fresenius Medical Care) were used for both modes and exchanged on a regular basis as described by the manufacturer. The microbiological quality was monitored and documented according to Hungarian law on a quarterly basis with the requirements of CFU in the dialysate ! 100/ml. Specifi c data on the infl ammatory response from 27 patients have been analysed in more depth and are published in a separate publication [15] .The set dialysate temperature at the HD machines was identical in HD and oHDF. The dialysate composition was identical in HD and oHDF; the calcium concentration in the dialysate was 1.75 mmol/l.
Study Parameters
Patient characteristics (such as age, gender, height, dry weight), their medical history and co-morbid diseases were recorded.
For each dialysis session the treatment parameters and the occurrence of intradialytic morbid events (IMEs) were noted. An IME (e.g. symptomatic hypotension, muscle cramps, dizziness, nausea, headache) was defi ned by a typical symptom, severe enough for the nurse to counteract. Thus, neither a single symptom (without necessity of a counter-measure), nor a therapeutical intervention (e.g. a transient reduction of the ultrafi ltration rate to prevent the symptom) was counted as IME. Intradialytic hypotension was not defi ned in advance as a fi xed decrease of the blood pressure in time, but assessed by the nurse.
The following parameters were monitored and documented monthly: treatment dose eKt/V, haematocrit, haemoglobin, serum ferritin, transferrin, C-reactive protein, serum calcium and serum phosphate, moreover weekly erythropoietin and iron dose. At the end of each study phase, the following blood parameters were measured mid-week, pre-dialysis: interleukin-6 (IL-6), myeloperoxidase (MPO), fi brinogen, albumin, lipoproteins, triglycerides, pentosidines (free and protein-bound), carboxy-methyl-lysine (CML), advanced oxidation protein products (AOPP), homocysteine, and parathyroid hormone (PTH). ␤ 2 -Microglobulin ( ␤ 2m) was only determined in a smaller subgroup of patients.
IL-6 was determined by an immunoassay (Quantikine, R&D British Biotechnology Ltd, UK). High-performance liquid chromatography (HPLC) with fl uorescence detection [16] has been utilised for the rapid determination of total homocysteine. AOPP were determined by a spectrophotometric assay. CML was quantifi ed by an enzyme-linked immunosorbent assay (ELISA) using the CMLspecifi c monoclonal antibody 4G9 (research assay provided by Roche Diagnostics GmbH, Penzberg, Germany) [17] . Free and protein-bound pentosidine were determined by an HPLC assay [18] .
Statistical Evaluation
The primary outcome parameter was cardiovascular stability (a comparison of the number of treatments with IME during the different treatment modalities). Sample size estimation was based on results of Pizzarelli et al. [8] and used the statistical method of Hills and Armitage [19] for cross-over trials. A signifi cance level of 5%, a power of 80%, and a drop-out rate of 30% per year was assumed. Based on these assumptions, a minimum sample size of 64 patients was fi xed in the study protocol. The infl uence of HD and oHDF on anaemic status was a secondary parameter.
All data was entered into an electronic database; statistical analysis was performed using SPSS for Windows, version 10.0 . Analyses were carried out by 2 test, Student's t-test for paired samples, Mann-Whitney test, and Wilcoxon signed rank test, where appropriate. Results are presented as mean 8 SD.
According to a recently published paper, haematocrit values were, in addition to the planned evaluation of data, checked for seasonal variations and adjusted accordingly [20] . The seasonal variation for haematocrit is taken into account by the formula HCT corrected = HCT measured -/ 2 ⌬ mean sin ( (4-m)/6), with m indicating the month (e.g. m = 1 for January, m = 2 for February). Seasonal variations in clinical and laboratory variables among HD patients were found, in some cases probably due to outdoor temperatures, but in most cases without apparent reason. The authors recommended considering these seasonal variations to avoid bias in the interpretation of clinical studies [20] . Pre-dialysis haematocrit values were found to be at minimum in January and at maximum in July. Due to the start of our study and enrolment of all patients in October, the fi rst study phase was in the cold season, whereas the second phase of the study was in the warm season.
Results
Study Population 129 patients were enrolled and randomised into group A or B. In the fi rst 3 weeks of each study phase, attempts were made to adjust treatment parameters to deliver a treatment dose eKt/V 6 1.2. During these periods Kt/V was measured weekly, thereafter monthly. Patients with a repeatedly lower treatment dose were withdrawn from the trial. The withdrawn patients (39 in total, thereof 27 male) were considerably heavier than the patients with a suffi cient dose ( table 1 ) . Largely due to the withdrawal of heavier male patients, the gender imbalance aggravated. For online HDF and HD a comparable percentage of patients were withdrawn. The overall mean blood fl ow rate during all treatments was 294 ml/min ( table 2 ) . However, those patients withdrawn from the study due to low dose during on-line HDF had a lower mean blood fl ow rate of 270 ml/min, increasing the diffi culty to reach the goal of eKt/V 6 1.2. The combination of both, heavy weight and limited blood fl ow, might have made it diffi cult to reach the goal of eKt/V 6 1.2.
In addition to this, 20 patients dropped out during the study (mainly due to transplantation (11) and death (4)), with comparable drop-out rates between male and female patients. The total drop-out rate over 1 year has been 16%.
Only the patients who completed the study were taken into account for evaluation (cohort of study completers). The patient characteristics of these 70 patients are presented in table 3 .
The majority of the patients suffered from hypertension ( table 3 ) . Antihypertensive medication was prescribed in 86% of the patients with 2.1 8 1.4 different antihypertensives (range 0-6). Moreover, in 74% of the patients drugs having an indirect infl uence on blood pressure such as nitrates or diuretics were prescribed (number of different medications 1.7 8 0.8, range 0-4).
Differences of the presented patient characteristics between both study groups were not statistically signifi cant. Only the imbalance of gender showed a trend: the percentage of male patients was lower in group B than in group A (p = 0.081).
Treatment
During the study, in total 10,144 treatments of 70 patients completing the study were documented. The mean volume of the on-line prepared substitution fl uid during oHDF was 20.3 8 3.0 litres. Details of the measured treatment parameters are listed in table 2 .
No statistically signifi cant difference in session length was observed for HD and oHDF. The mean blood fl ow rate of 294 ml/min was low for post-dilutional oHDF. According to protocol it was tried to minimise the difference in dialysis dose between HD and oHDF (e.g. by increase of blood fl ow during HD), nevertheless, oHDF still presented with a signifi cantly higher dialysis dose.
For the incidence of IMEs (the primary outcome parameter) no statistically signifi cant difference between both treatment modalities was found: in pooled data 0.15 IME per session for HD and 0.16 IME per session for oHDF (see table 2 for the results per group). Patients with a diuresis ^100 ml/day are defi ned as anuric (*), residual diuresis is calculated only for non-anuric patients (**). Table 3 . Baseline data in both study groups of the cohort of study completers ond study phase, independently of the treatment mode HD or oHDF (change of reimbursement policy in Hungary). Only a minority of patients was supplemented orally with iron (A: 8%, B: 12%, ns). Erythropoietin dose was less during oHDF in both groups, however not statistically signifi cant in group A. In spite of this, a statistically signifi cant increase in haematocrit and haemoglobin was found during oHDF, ; 5% in group A (p ! 0.023). Details within the study phases concerning the delivered erythropoietin dose and the measured haemoglobin values are given in fi gure 1 . The course of both parameters during the study phases are characterised by the displayed mean values which cover 8-week intervals within each study phase.
Control of Anaemic Status
Serum ferritin levels were lower in the second than in the fi rst study phase, independently of the treatment mode due to reduced iron supply. As a result, the erythropoietin resistance index (weekly erythropoietin dose per kilogram body weight divided by haemoglobin) was higher for HD than for oHDF only in group B ( table 4 ) .
Seasonal variations were found for the mean pre-dialysis haematocrit values, with an amplitude between minimum (in January) and maximum (in July) of 0.6% [20] . Seasonal variation analysis in our patients revealed a difference of ⌬ mean = 0.67%, which was statistically signifi cant (p = 0.03). The start of our study and the enrolment of all patients was in October, in the cold season, whereas the second phase of the study was in the warm season. The mean haematocrit of all patients irrespective of group allocation was 30.7 8 2.8% for weeks 1-24 and 31.3 8 3.2% for weeks 25-48. The amplitude of this sineshaped variation was calculated to be 1.05% ( ⌬ ampl = / 2 ⌬ mean ). Using the formula described in the Methods, the haematocrit without seasonal variation was calculated to be 30.8 ( table  4 ) . Originally, the mean differences between HD and oHDF were not balanced in both groups for the measured haematocrit values: ⌬ HCT meas = HCT oHDF -HCT HD = 1.6% in group A, but only ⌬ HCT meas = 0.1% in group B.
After correction for seasonal variation these mean differences between HD and oHDF became nearly identical:
⌬ HCT corr = 0.89% in A, and ⌬ HCT corr = 0.91% in B.
Blood Parameters
The mean values of the measured biochemical parameters of the blood are given in table 5 . Whereas MPO increased and fi brinogen decreased signifi cantly during the second treatment phase independently of the treatment mode, serum albumin presented with nearly identical values. In contrast, IL-6 decreased during oHDF in parallel with CRP and fi brinogen, but only in group A.
Whereas CML was not different between treatment modes or phases, free pentosidine and protein-bound pentosidine signifi cantly decreased in both groups (see fi g. 2 ) during oHDF; AOPP, however, only in group A. The parameters are interleukin-6 (IL-6), C-reactive protein (CRP), myeloperoxidase (MPO), fi brinogen (Fb), albumin (Alb), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TG), carboxymethyllysine (CML), free pentodisine (f-Pe), proteinbound pentosidine (pb-Pe), advanced oxidation protein products (AOPP), homocysteine (Hcy), parathyroid hormone (PTH), calcium (Ca), phosphate (Pi), calcium phosphate product (CaxP), and ␤ 2 -microglobulin (␤2m). Signifi cance of the intra-individual comparison between the study phases by Wilcoxon signed rank test is indicated by ns for p 6 0.05, by * for p < 0.05 and by ** for p < 0.01. As bone metabolism may also infl uence anaemia correction, these parameters were also investigated. Vitamin D (calcitriol) was supplemented in 19 patients (A: 8, B:
11), with a mean value of 0.8 8 0.7 g/week. PTH was lower in the second study phase, independent from the treatment mode. Serum calcium level did not change, whereas serum phosphate was observed to be signifi cantly lower during oHDF in both groups (A: -9%, B: -14%, see fi g. 3 ), as was the calcium-phosphate product.
␤ 2m was measured only in a subgroup of patients: 21 out of 36 patients could be analysed in group A and 22 out of 34 patients in group B. In group A, ␤ 2m was found to be only marginally lower for oHDF than for low-fl ux HD (median for HD and oHDF: 28.0 and 25.9 mg/l, respectively, for mean values see table 5 ). In group B, signifi cantly lower values of ␤ 2m were observed during oHDF than during low-fl ux HD (median for oHDF and HD: 28.2 and 41.2 mg/l, respectively, for mean values see table 5 ). The reason for the different effects in groups A and B remain unclear.
Discussion
129 patients started this prospective study, of which 70 patients completed the planned 24 weeks each on HD and oHDF in randomised order. 39 patients were withdrawn from the study due to the study-specifi c requirement of the minimum equilibrated dialysis dose eKt/V of at least 1.2, and another 20 patients dropped out due to common reasons such as transplantation and death. The required minimum dialysis dose turned out to aggravate an imbalance of gender between both groups. Even though there was no statistically signifi cant difference between the two patient groups completing the study, with p = 0.08 a trend to fewer male patients in group B was observed. Other differences concerning patient characteristics such as the prevalence of hypertension, the number of anuric patients, and the mean residual renal function are also mentionable. Although not statistically signifi cant, these differences between the two study groups may contribute to the different observations for some parameters.
An identical membrane material (polysulfone) was applied in both treatment modes, but low-fl ux dialysers were used during HD whereas high-fl ux dialysers were applied during oHDF. Although a direct comparison of oHDF and high-fl ux HD demonstrated an advantage of oHDF in small and middle molecular clearance [12] , some of the benefi t found in the oHDF phase could have been due to the use of high-fl ux dialysers, rather than to oHDF.
For many investigated parameters the results were comparable for oHDF and for HD, and for many parameters better results were found for oHDF than for HD; no result in favour of HD was observed.
During oHDF we observed an improved anaemia control, either with increase of haematocrit at the same erythropoietin dose (group A), or with comparable haematocrit at reduced erythropoietin dose (group B).
As availability of erythropoietin was limited the mean erythropoietin dose was not prescribed according to an optimal target level. In addition, iron reimbursement changed during the second half of the study and patients had to substantially contribute to the payment, so that the overall dose decreased. As a consequence, most haematocrit and haemoglobin values were below targets (33% and 11 g/dl, respectively) recommended in guidelines on anaemia management [21] . The intravenous iron dose was in the lower half of the recommended range [21] , even more so in the second study phase. In group A, less intravenous iron was supplied during oHDF than during HD (-26%, p ! 0.01), at the same erythropoietin dose (-4%, ns), nevertheless, a higher haematocrit was observed (5%, p ! 0.01). In group B, during oHDF more intravenous iron was supplied (27%, p ! 0.01) but less erythropoietin (-20%, p ! 0.01) and the haematocrit was found to be 1% higher (ns). Whether this nearly identical value for hae- matocrit at a lower erythropoietin dosage during oHDF in group B is the consequence of a higher intravenous iron dose, or the consequence of the oHDF treatment mode, remains open. The increased erythropoietin resistance for female patients compared to male patients is most pronounced in young patients and decreases with age [22] . For our intra-individual comparison, this gender-associated difference between male and female patients is less important. We found a lower erythropoietin resistance index for online HDF compared to HD in both study groups, but statistically signifi cant only in group B with a predominantly female population.
Seasonal variations in clinical and laboratory variables among 1,445 chronic HD patients were found, in some cases probably due to outdoor temperatures, but in most cases without apparent reason. The authors recommended to consider these seasonal variations to avoid bias in the interpretation of clinical studies [20] . Due to the start of our study and enrolment of all patients in October, the fi rst study phase was in the cold season, whereas the second phase of the study was in the warm season. Another recent study among 34 HD patients reported of seasonal variations of several blood parameters, but did not fi nd an impact on haemoglobin levels [23] . The amplitude of the seasonal variation of haematocrit was with a value of 1.05% even more pronounced in the Hungarian study population than the value of 0.6% found in the American population. An explanation for the weaker effect observed in US patients might be the heterogeneous climate in the area of the participating dialysis centres in between 30 and 50 latitude in the northern hemisphere, and from west to east coast of the United States. In contrast to this, less distinct climatic differences are expected between the various locations in Hungary. In our patient population the positive impact of oHDF in the treatment of anaemia is statistically signifi cant in both study groups, if the effect of seasonal variation is taken into account ( table 4 ). The neglected superposition of the seasonal variation may have covered the underlying increase of haematocrit due to oHDF in other studies.
The role of ultrapure water for dialysis and thereby less infl ammatory stimulus with the consequence of less advanced glycation end product (AGE) formation and less oxidation was considered to be an important aspect of better results with oHDF treatment in other investigations [24] [25] [26] . In our study a dialysate fi lter (Diasafe ® ) was used for low-fl ux dialysis HD as well as for oHDF. The markers for infl ammation such as CRP and IL-6 were lower in group A after oHDF, whereas there was no difference in group B. A detailed analysis covering this item in a subpopulation of this study (27 patients) did not show any difference in plasma cytokine levels between the different treatment modalities, the substitution fl uid did not provoke an additional infl ammatory stimulus [15] . The difference in erythropoietic response cannot be explained by a difference based on water or dialysate quality, but may be associated to increased convective fl ux, possibly supporting recently published mechanisms of anaemia improvement by elimination of phosphatidylserine [27] .
AOPP, formed during oxidative stress [26, 28] , and AGEs were effectively reduced during oHDF not only in the free form of pentosidine, but also in its protein-bound form, accounting for more than 90% of its total amount. This suggests that indeed less oxidation was responsible for the lowered protein-bound fraction. Other studies have shown that by convective transport such as high-fl ux dialysis [18, 29] , several of these AGE compounds may be markedly reduced. However, in other investigations a constant lowering of pre-dialysis levels with oHDF or HF was only found when ultrapure water was used [24] [25] [26] .
Recently a correlation was found between AGEs, AOPP and triglycerides (e.g. r = 0.68 for linear correlation between triglycerides and AGEs) [30] . During oHDF we observed a 15% lower mean value of triglycerides in one group and a 16% increase of HDL in the other group, whereas LDL did not change signifi cantly.
Increase of MPO and decrease of fi brinogen did not change treatment-dependent, just phase-or season-dependent. Albumin remained unchanged. There is no obvious explanation for these fi ndings, and possibly the sample size and the length of the investigation do not allow a meaningful interpretation.
Hyperphosphataemia is a major determinant of morbidity and mortality in HD patients [31] . It was recently reported that even a mild hyperphosphataemia ( 1 1.61 mmol/l) might be independently associated with an increased risk for death in HD patients [32] . Dialysis centres with increased frequency of dialysis treatment or prolonged duration of the treatment report successful prevention of hyperphosphataemia; for oHDF also increased removal compared to HD has been demonstrated [33, 34] . In our study a constant lowering of the calcium-phosphate product was found only due to the lowering of phosphate. With a mean value of 1.80 mmol/l in the pre-phase our patients had a mild hyperphosphataemia, and mean phosphate values were 1.49 mmol/l (vs. 1.62) for group A and 1.57 mmol/l (vs. 1.85) for group B during oHDF. In this study convective solute transport in oHDF improved the elimination of phosphate such that a constant lowering of serum phosphate levels was possible, which has been not described before to our knowledge.
The incidence of IME was low in our patient population (mean 0.154 IME per session). After covering 10,144 treatments, we did not fi nd a decrease of frequency of symptomatic hypotension during oHDF. The better intradialytic cardiovascular stability of oHDF compared to HD found by others [8] is probably due to cooling of the blood via enhanced thermal energy losses within the extracorporeal circuit in case of oHDF. A comparison of the effect of oHDF with HD and temperature-controlled HD on the haemodynamic stability of hypotension-prone patients showed no difference in the rate of hypotensive episodes, if the energy transfer rates from the dialysate to the blood were identical in oHDF and HD [35] . In our study the identical set temperature at the HD machines in oHDF and HD should result in a slightly lower temperature of the returning blood in the venous line during oHDF compared to HD. This cooling should result in a better cardiovascular stability. On the other hand, with an infusion of 20 litres of on-line prepared substitution fl uid, a larger amount of bicarbonate is given to the patient during oHDF than during HD. Recently, an increase of hypotensive episodes has been demonstrated as a result of a transient mild metabolic alkalosis induced by bicarbonate transferred from the dialysis fl uid [36] . During oHDF the superposition of the effects of bicarbonate load (inducing peripheral vasodilation) and of cooling (inducing peripheral vasoconstriction) may have led to a cardiovascular stability which is not different from that observed during HD.
In summary, even though many unforeseen circumstances prevented an ideal course of the study, our results, in accordance with others [5, 7] , demonstrate that on-line HDF is of clinical and practical importance in the management of anaemia in HD patients, and may have a benefi cial effect on infl ammation, oxidative stress, lipid profi les, and calcium-phosphate product, i.e. cardiovascular risk profi les. Larger trials with longer treatment periods will help to answer remaining questions.
